NCT02695537View on ClinicalTrials.gov

University of Alabama at Birmingham (UAB) Pediatric CBD Program

PHASE1CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

February 27, 2019

Study Completion Date

February 27, 2019

Conditions
EpilepsySeizures
Interventions
DRUG

Epidiolex

Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).

Trial Locations (1)

35233

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT02695537 - University of Alabama at Birmingham (UAB) Pediatric CBD Program | Biotech Hunter | Biotech Hunter